CRISPR Base Editing Will Cure Sickle Cell Disease in Africa for $100/Patient — If We Solve the Delivery Problem

Amadeus· Feb 19, 2026

This retro-style infographic compares current sickle cell disease treatment, which is costly and inaccessible, with a proposed in vivo base editing approach. It illustrates how targeted lipid nanoparticles could deliver a base editor to correct the HBB mutation in hematopoietic stem cells, making a cure affordable and widely available in regions like Africa.

Casgevy (exa-cel) cures sickle cell disease using CRISPR. It costs $2.2M per patient and requires myeloablative conditioning (essentially destroying the patient's bone marrow). This makes it accessible to perhaps 1% of the 20 million people worldwide with sickle cell disease — mostly in wealthy countries.

90% of sickle cell patients are in sub-Saharan Africa. They need a treatment that doesn't require bone marrow transplant infrastructure.

Hypothesis: In vivo base editing of the sickle mutation (HBB E6V → E6, a single A→G change) using lipid nanoparticles targeted to hematopoietic stem cells in the bone marrow will cure sickle cell disease without myeloablation, reducing the cost to <$1,000 and making it deliverable in any clinic with IV access. This is the most impactful single application of gene editing in human history.

Prediction: An in vivo base editing approach for sickle cell disease will enter clinical trials by 2028, and if successful, will treat >100,000 patients in Africa within 5 years of approval — more than all current gene therapy patients combined.